Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20559738 | 1.00 | CYP2A6 (0.46) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12356972 | 0.86 | CYP2A6 (0.49) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL28321258 | 0.83 | CYP2A6 (0.46) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8502957 | 0.76 | PLAU (0.39) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL177345 | 0.75 | CYP2A6 (0.52) | CYP2A6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL20559086 | 0.74 | CA12 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20559684 | 0.74 | ALOX5 (0.57) | ALOX5GPR35CYP19A1CA1CA2 | |
| SCHEMBL8898552 | 0.74 | CA12 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20559632 | 0.74 | CA12 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9826669 | 0.74 | PIM1 (0.50) | CYP2A6CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3404021-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
| EP-0587110-B1 | Condensed heterocyclic derivatives and agricultural or horticultural fungicides containing the same | KUMIAI CHEMICAL INDUSTRY CO (JP) | 1997-12-17 | — | — | EP | disclosed |
| EP-0587110-A2 | Condensed heterocyclic derivatives and agricultural or horticultural fungicides containing the same | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | CACNA1I, CACNA1G, CACNA1E | CYP2A6 1405/4885CHRM2 198/4885CHRM4 289/4885 |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1E | CYP2A6 1475/4885CHRM2 172/4885CHRM4 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.